Levi & Korsinsky notifies investors that it has commenced an investigation into GRAIL, Inc. (NASDAQ: GRAL) concerning potential violations of the federal securities laws.
On the Q3 2025 earnings call on November 12, 2025, CFO Aaron Freidin told investors the Company was "updating our cash-burn guidance further to no more than $290 million for the full year of 2025." In the same remarks, CEO Robert Ragusa stated: "We believe our cash runway extends into 2030, enabling us to achieve major planned clinical and regulatory milestones." Those milestones included completion of the FDA PMA submission and full clinical-utility results from the 140,000-participant NHS Galleri study. The cash-burn figure and runway projection were presented as sufficient to fund a pathway that, following the trial's failure, may require additional studies, revised timelines, or materially different capital needs.
If you suffered a loss on your GRAIL, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks.
We monitor critical case developments that may affect the price of your shares and your possible monetary recovery.
SnapTrade only shares the tickers you own and your transaction history — not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create an attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery — link your brokerage account with SnapTrade.